» Articles » PMID: 35801207

Hypertonic Solution in Severe COVID-19 Patient: A Potential Adjuvant Therapy

Overview
Specialty General Medicine
Date 2022 Jul 8
PMID 35801207
Authors
Affiliations
Soon will be listed here.
Abstract

Coronavirus disease 2019 (COVID-19) features hyper-inflammation, cytokine storm, neutrophil function changes, and sodium chloride (NaCl) homeostasis disruption, while the treatment with NaCl hypertonic solutions (HS) controls electrolytic body homeostasis and cell functions. HS treatment is a simple, popular, economic, and feasible therapy to regulate leukocyte function with a robust anti-inflammatory effect in many inflammatory diseases. The purpose of this narrative review is to highlight the knowledge on the use of HS approaches against viral infection over the past years and to describe the mechanisms involved in the release of neutrophil extracellular traps (NETs) and production of cytokine in severe lung diseases, such as COVID-19. We reported the consequences of hyponatremia in COVID-19 patients, and the immunomodulatory effects of HS, either or . We also described the relationship between electrolyte disturbances and COVID-19 infection. Although there is still a lack of clinical trials, hypertonic NaCl solutions have marked effects on neutrophil function and NETs formation, emerging as a promising adjuvant therapy in COVID-19.

Citing Articles

Effectiveness of hypertonic saline with or without hyaluronic acid among patients with cystic fibrosis: a systematic review and meta-analysis.

Khan Z, Naeem M, Amin D, Amin L, Shah A, Khaliq S Ann Med Surg (Lond). 2024; 86(10):6091-6096.

PMID: 39359762 PMC: 11444569. DOI: 10.1097/MS9.0000000000002450.


The effectiveness of hyaluronic acid in reducing adverse effects associated with inhaled hypertonic saline therapy in patients with cystic fibrosis: A systematic review and meta-analysis.

Arshid S, Ullah S, Imran J, Syed M, Choradia A, Gousy N Can J Respir Ther. 2023; 59:214-222.

PMID: 37927455 PMC: 10621800. DOI: 10.29390/001c.89093.

References
1.
Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L . Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study. Clin Infect Dis. 2020; 71(15):889-890. PMC: 7184514. DOI: 10.1093/cid/ciaa330. View

2.
Reeves E, Williamson M, ONeill S, Greally P, McElvaney N . Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis. Am J Respir Crit Care Med. 2011; 183(11):1517-23. DOI: 10.1164/rccm.201101-0072OC. View

3.
Aitken M, Greene K, Tonelli M, Burns J, Emerson J, Goss C . Analysis of sequential aliquots of hypertonic saline solution-induced sputum from clinically stable patients with cystic fibrosis. Chest. 2003; 123(3):792-9. DOI: 10.1378/chest.123.3.792. View

4.
Daviskas E, Anderson S . Hyperosmolar agents and clearance of mucus in the diseased airway. J Aerosol Med. 2006; 19(1):100-9. DOI: 10.1089/jam.2006.19.100. View

5.
Schaeffer V, Arbabi S, Garcia I, Knoll M, Cuschieri J, Bulger E . Role of the mTOR pathway in LPS-activated monocytes: influence of hypertonic saline. J Surg Res. 2010; 171(2):769-76. PMC: 3006012. DOI: 10.1016/j.jss.2010.05.035. View